Novo Nordisk: grants Innate Pharma rights on antibody drug.
(CercleFinance.com) - Innate Pharma has announced its signing of an agreement, under which Novo Nordisk grants it all of the exclusive development and marketing rights of the anti-C5aR antibodies, which becomes the program IPH5401.
Currently at the clinical stage, this "first-in-class" antibody consolidates the company's position in targeting the microenvironment tumour beyond its developments that target the adenosine pathway. Clinical trials in Oncology are scheduled to begin in 2018.
The agreement includes an upfront payment of 40 million euros, mainly in new shares. Novo Nordisk will be eligible to milestone payments of up to 370 million euros and royalties based on future sales of over 10%.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Currently at the clinical stage, this "first-in-class" antibody consolidates the company's position in targeting the microenvironment tumour beyond its developments that target the adenosine pathway. Clinical trials in Oncology are scheduled to begin in 2018.
The agreement includes an upfront payment of 40 million euros, mainly in new shares. Novo Nordisk will be eligible to milestone payments of up to 370 million euros and royalties based on future sales of over 10%.
Copyright (c) 2017 CercleFinance.com. All rights reserved.